2. Cell Cycle/DNA Damage Apoptosis Stem Cell/Wnt PI3K/Akt/mTOR
  3. CDK Caspase Apoptosis GSK-3
  4. PHA-793887 hydrochloride

PHA-793887 hydrochloride is a CDK inhibitor (with IC50 values of 8 nM for Cdk2, 60 nM for Cdk1, 62 nM for Cdk4, 138 nM for Cdk9). PHA-793887 hydrochloride inhibits purified GSK3β (IC50 79 nM). PHA-793887 hydrochloride reduces the phosphorylation level of nucleophosmin/cdc6, induces G1/G2/M phase arrest, and triggers Apoptosis by activating Caspase-3. PHA-793887 hydrochloride exhibits anticancer activity against leukemia. PHA-793887 hydrochloride can be used in research related to acute leukemia, chronic myeloid leukemia, and advanced/metastatic solid tumors.

For research use only. We do not sell to patients.

PHA-793887 hydrochloride

PHA-793887 hydrochloride Chemical Structure

CAS No. : 718630-60-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of PHA-793887 hydrochloride:

Other Forms of PHA-793887 hydrochloride:

PHA-793887 hydrochloride Related Antibodies

Top Publications Citing Use of Products

View All CDK Isoform Specific Products:

View All Isoforms
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All GSK-3 Isoform Specific Products:

View All Isoforms
GSK-3 GSK-3α GSK-3β

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PHA-793887 hydrochloride is a CDK inhibitor (with IC50 values of 8 nM for Cdk2, 60 nM for Cdk1, 62 nM for Cdk4, 138 nM for Cdk9). PHA-793887 hydrochloride inhibits purified GSK3β (IC50 79 nM). PHA-793887 hydrochloride reduces the phosphorylation level of nucleophosmin/cdc6, induces G1/G2/M phase arrest, and triggers Apoptosis by activating Caspase-3. PHA-793887 hydrochloride exhibits anticancer activity against leukemia. PHA-793887 hydrochloride can be used in research related to acute leukemia, chronic myeloid leukemia, and advanced/metastatic solid tumors[1][2][3][4].

IC50 & Target[4][3]

CDK2

8 nM (IC50)

CDK1

60 nM (IC50)

CDK4

62 nM (IC50)

CDK9

138 nM (IC50)

Caspase 3

 

GSK-3β

79 nM (IC50)

In Vitro

PHA-793887 hydrochloride potently inhibits multiple cyclin-dependent kinases with IC50 values between 5 and 140 nM, and is inactive against non-cdk kinases including c-abl, c-kit, lck, and TRKA[1].
PHA-793887 (0.01-10 μM; 48 h) hydrochloride is cytotoxic to a panel of leukemic cell lines with IC50 values from 0.04 μM to >10 μM, is not cytotoxic to unstimulated normal PBMC and CD34+ cells, and inhibits proliferation of mitogen- or growth factor-stimulated normal hematopoietic cells with IC50 values of 0.75 μM and 1.85 μM, respectively[1].
PHA-793887 (0.04-5 μM; 48 h; 24 h) hydrochloride induces G1 phase cell cycle arrest at 0.04 to 1 μM and apoptosis at 5 μM in sensitive leukemic cell lines (697, KCL22, TOM1), but has no effect on resistant KG1 cells; it activates caspase-3 in KCL22 cells at 5 μM[1].
PHA-793887 hydrochloride potently inhibits multiple CDKs, including CDK2/cyclin A (IC50 = 0.008 μM), and shows selective activity against GSK3β among a panel of non-CDK kinases[3].
PHA-793887 hydrochloride inhibits proliferation of a broad range of human cancer cell lines, with the highest potency against colon carcinoma HCT-116 cells (IC50 = 0.163 μM) and lowest potency against pancreatic carcinoma BX-PC3 cells (IC50 = 3.444 μM)[3].
PHA-793887 (1-3 μM; 24 h) hydrochloride disrupts cell cycle progression and inhibits DNA synthesis in human ovarian carcinoma A2780 cells, inducing G1 arrest at 1 μM and G2/M arrest with apoptosis at 3 μM[3].
PHA-793887 hydrochloride potently inhibits purified Cdk2 (IC50 8 nmol/L), Cdk1 (IC50 60 nmol/L), Cdk4 (IC50 62 nmol/L), Cdk9 (IC50 138 nmol/L), and GSK3β (IC50 79 nmol/L) in cell-free biochemical assays, while sparing 35 other tested kinases[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PHA-793887 hydrochloride Related Antibodies

Cell Viability Assay[1]

Cell Line: 13 leukemic cell lines (K562, KCL22, KU812, TOM1, SUP-B15, REH, 697, RS4;11, HL60, KG1, RPMI8226, ALL-2, AML-PS), normal unstimulated peripheral blood mononuclear cells (PBMC), phytohemagglutinin-stimulated PBMC, normal unstimulated CD34+ hematopoietic stem cells, growth factor cocktail-stimulated CD34+ hematopoietic stem cells
Concentration: 0.01-10 μM
Incubation Time: 48 h
Result: Showed variable cytotoxicity across leukemic cell lines, with IC50 values ranging from 0.04 μM (most sensitive lines: TOM1, 697, RS4;11, HL60) to >10 μM (least sensitive lines: SUP-B15, KG1).
Primary leukemic cells ALL-2 and AML-PS had IC50 values of 3.4 μM and 6.2 μM, respectively.
Was not cytotoxic to unstimulated normal PBMC or CD34+ cells (IC50 >10 μM), but inhibited proliferation of stimulated PBMC (IC50 0.75 μM) and stimulated CD34+ cells (IC50 1.85 μM).

Cell Cycle Analysis[1]

Cell Line: 697, KCL22, TOM1, and KG1 leukemic cell lines
Concentration: 0.04-5 μM
Incubation Time: 48 h (cell cycle analysis); 24 h (apoptosis analysis)
Result: Induced G1 phase arrest (14-40% increase compared to control) and reduced S-phase cell counts at doses of 0.04 to 1 μM in sensitive cell lines (697, KCL22, TOM1).
Induced a G2/M phase block (34% increase) in TOM1 cells at 1 μM.
Induced apoptosis (15-35% sub-G1 population) in sensitive cell lines at 5 μM.
Showed no significant cell cycle arrest or apoptosis in resistant KG1 cells at any dose.
Induced caspase-3 activation (43% positive cells, a 26% increase compared to control) in KCL22 cells at 5 μM, while 0.2 μM had no effect.

Cell Cycle Analysis[3]

Cell Line: human ovarian carcinoma A2780 cells
Concentration: 1-3 μM
Incubation Time: 24 h
Result: Caused a 25% increase in G0/G1 population, 76% decrease in S phase population, 62% increase in G2/M population, and 85% reduction in BrdU incorporation relative to control at 1 μM.
Caused an 11% decrease in G0/G1 population, 48% decrease in S phase population, 263% increase in G2/M population, 100% reduction in BrdU incorporation, and an increase in sub-G1 cells (from 2.6% to 26.2%) indicative of apoptosis at 3 μM.
Parmacokinetics
Species Dose Route Cmax AUC CL T1/2 Vss
Mice[3] 10 mg/kg i.v. 36.5 μM 19.2 μM·h 23.9 mL/min/kg 4.1 h 1360 mL/kg
In Vivo

PHA-793887 (20 mg/kg; i.v.; once daily; 10 consecutive days) hydrochloride induces tumor regression and a 23.3-day growth delay in HL60 subcutaneous AML xenografts in SCID mice[1].
PHA-793887 (20 mg/kg; i.v.; once daily; two 5-day cycles with 3-day rest between cycles) hydrochloride significantly reduces tumor growth and causes a 4.7-day growth delay in K562 subcutaneous CML xenografts in SCID mice[1].
PHA-793887 (20 mg/kg; i.v.; once daily; three 5-day cycles with 3-day rests between cycles) hydrochloride significantly increases median survival by 7 days in the preemptive disseminated AML-PS xenograft model in SCID mice[1].
PHA-793887 (20 mg/kg; i.v.; once daily; three 5-day cycles with 3-day rests between cycles) hydrochloride significantly increases median survival by 22.5 days in the preemptive disseminated ALL-2 xenograft model in SCID mice[1].
PHA-793887 (10-30 mg/kg; i.v.; daily; 10 days) hydrochloride exhibits 76% tumor growth inhibition in human A2780 ovarian carcinoma xenografts when administered at 30 mg/kg i.v. daily for 10 days, with confirmed in vivo target engagement via reduced tumor cell proliferation and pRb phosphorylation[3].
PHA-793887 (10-20 mg/kg; i.v.; daily; 10 days) hydrochloride exhibits 81% tumor growth inhibition in human HCT-116 colon carcinoma xenografts when administered at 20 mg/kg i.v. daily for 10 days, with good tolerability[3].
PHA-793887 (20 mg/kg; i.v.; daily; 10 days) hydrochloride exhibits 84% tumor growth inhibition in human BX-PC3 pancreatic carcinoma xenografts when administered at 20 mg/kg i.v. daily for 10 days, with good tolerability[3].
PHA-793887 (15-30 mg/kg; i.v.; daily; 2-10 days) hydrochloride induces dose-dependent tumor growth inhibition (50% at 15 mg/kg, 75% at 30 mg/kg) and downregulation of an E2F-dependent gene signature in A2780 ovarian carcinoma xenografts in CD-1 nude mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID mice (unspecified gender, age not specified)[1]
Dosage: 20 mg/kg
Administration: i.v.; once daily; 10 consecutive days
Result: Induced tumor regression.
Achieved a tumor growth delay of 23.3 days.
Left all treated mice tumor-free one week after treatment ended.
Caused no body weight loss or toxic effects.
Animal Model: SCID mice (unspecified gender, age not specified)[1]
Dosage: 20 mg/kg
Administration: i.v.; once daily; two 5-day cycles with 3-day rest between cycles
Result: Significantly reduced tumor growth from day 14 compared to vehicle controls (p < 0.01).
Achieved a tumor growth delay of 4.7 days.
Caused no body weight loss or toxic effects.
Animal Model: SCID mice (5-week-old, unspecified gender)[1]
Dosage: 20 mg/kg
Administration: i.v.; once daily; three 5-day cycles with 3-day rests between cycles
Result: Significantly increased median survival time by 7 days compared to vehicle controls (p < 0.0001).
Animal Model: SCID mice (5-week-old, unspecified gender)[1]
Dosage: 20 mg/kg
Administration: i.v.; once daily; three 5-day cycles with 3-day rests between cycles
Result: Significantly increased median survival time by 22.5 days compared to vehicle controls (p < 0.0001).\nSignificantly increased median survival time by 22.5 days compared to vehicle controls (p < 0.0001).
Reduced tumor infiltration from 22.5% to 1.6% in peripheral blood after two treatment cycles.
Reduced tumor infiltration from 97.7% to 24.8% in bone marrow after two treatment cycles.
Reduced tumor infiltration from 91.6% to 44.7% in spleen after two treatment cycles.
Caused no body weight loss or toxic effects.
Animal Model: Nu/Nu (male)[3]
Dosage: 10 mg/kg; 20 mg/kg; 30 mg/kg
Administration: i.v.; daily; 10 days
Result: Caused dose-dependent inhibition of A2780 tumor growth, reaching 76% tumor growth inhibition at the 30 mg/kg dose at the end of treatment.
Showed marginal body weight reduction (<10% vs control mice) and no toxic effects observed at gross autopsy.
Reduced tumor BrdU incorporation (p = 0.0022) and phosphorylated retinoblastoma protein (pRb) levels (p = 0.005) in mice treated with 30 mg/kg for 5 days compared to vehicle controls.
Animal Model: Nu/Nu (male)[3]
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.v.; daily; 10 days
Result: Caused dose-dependent inhibition of HCT-116 tumor growth, reaching 81% tumor growth inhibition at the 20 mg/kg dose at the end of treatment.
Showed marginal body weight reduction (<10% vs control mice) and no toxic effects observed at gross autopsy.
Animal Model: Nu/Nu (male)[3]
Dosage: 20 mg/kg
Administration: i.v.; daily; 10 days
Result: Caused 84% tumor growth inhibition in BX-PC3 xenografts at the end of treatment.
Showed marginal body weight reduction (<10% vs control mice) and no toxic effects observed at gross autopsy.
Molecular Weight

397.94

Formula

C19H32ClN5O2
CAS No.
SMILES

O=C(CC(C)C)NC1=NNC2=C1CN(C2(C)C)C(C3CCN(CC3)C)=O.Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PHA-793887 hydrochloride Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PHA-793887718630-60-5PHA793887PHA 793887CDKCaspaseApoptosisGSK-3Cyclin dependent kinaseGlycogen synthase kinase-3Glycogen synthase kinase 3CDK1CDK7leukemic cellsCDK5GSK3CDK4CDK2cyclin-dependent kinaseCDK9acute leukemiasInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PHA-793887 hydrochloride
Cat. No.:
HY-11001A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.